D. Cescon

发表论文 191 篇 · 总被引 7951 次 · h-index 36

代表论文

• Sacituzumab govitecan (SG) + pembrolizumab (pembro) vs chemotherapy (chemo) + pembro in previously untreated PD-L1–positive advanced triple-negative breast cancer (TNBC): Primary results from the randomized phase 3 ASCENT-04/KEYNOTE-D19 study. (2025 · Journal of Clinical Oncology · 被引 61)
• Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer. (2026 · New England Journal of Medicine · 被引 57)
• TROPION-Breast05: a randomized phase III study of Dato-DXd with or without durvalumab versus chemotherapy plus pembrolizumab in patients with PD-L1-high locally recurrent inoperable or metastatic triple-negative breast cancer (2025 · Therapeutic Advances in Medical Oncology · 被引 27)
• Personalized ctDNA monitoring in metastatic HR+/HER2− breast cancer patients during endocrine and CDK4/6 inhibitor therapy (2025 · npj Breast Cancer · 被引 10)
• A double-blind placebo controlled randomized phase III trial of fulvestrant and ipatasertib as treatment for advanced HER2-negative and estrogen receptor positive (ER+) breast cancer following progression on first line CDK 4/6 inhibitor and aromatase inhibitor: The CCTG/BCT MA.40/FINER study (NCT046 (2025 · Journal of Clinical Oncology · 被引 8)
• Abstract GS3-01: Circulating tumor DNA surveillance in ZEST, a randomized, phase 3, double-blind study of niraparib or placebo in patients w/ triple-negative breast cancer or HER2+ BRCA-mutated breast cancer with molecular residual disease after definitive therapy (2025 · Clinical Cancer Research · 被引 6)